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Conclusions: OxyLDL leads to impaired NO generation and
apoptotic cell death in BAEC. This effect occurs via overexpression
of LOX-1 and the subsequent attenuation of protective autophagic
response thereby contributing in the pathophysiology of oxyLDL-
induced endothelial dysfunction which characterizes early stages of
atherosclerotic process.
doi:10.1016/j.ijcme.2015.05.005
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Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one
of the scavenger receptors for oxidized low density lipoprotein (ox-LDL),
plays a crucial role in signaling pathways involved in the process of
oxidative stress and inﬂammation. As evidence supporting the vital role
of LOX-1 keeps accumulating, there is growing interest in LOX-1 as a
potential therapeutic target. Here, we review the discovery and genetics
of LOX-1, describe existing evidence supporting the role of LOX-1 in
atherogenesis and its major complication- myocardial ischemia, and
summarize its modulation by some naturally occurring compounds that
could be of therapeutic use.
Ox-LDL/LOX-1 relationship appears to be an important player in
the development of atherosclerosis and its sequelae, such as MI and
cardiac remodeling. The scavenger receptor LOX-1 activates most, if
not all, signaling from the beginning to culmination of major life-
threatening events related to this malady. From genetic studies, it is
quite evident that certain individuals have propensity to develop
CAD-related events. Since the current therapies of coronary heart
disease, mainly LDL-cholesterol lowering drugs, are ineffective in a
large number of patients, there is need for new targets that focus on
the underlying signals of the disease process. A host of strategies are
being proposed that would either block oxidation of LDL-cholesterol
and/or reduce the expression of LOX-1. While the development of
these strategies is eagerly awaited, some naturally occurring
compounds appear quite promising and deserve clinical trials.
doi:10.1016/j.ijcme.2015.05.006
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The endothelium regulates vascular homoeostasis through local
elaboration of mediators that modulate vascular tone, platelet
adhesion, inﬂammation, ﬁbrinolysis, and vascular growth. Impaired
vascular function contributes to the pathogenesis of atherosclerosis
and acute coronary syndromes. Impaired endothelial function is
associated with atherothrombotic risk factors and atherothrombotic
disease, is pathophysiologically linked to acute cardiovascular
syndromes. A central feature of impaired endothelial function in
the presence of cardiac risk factors and under pathological conditions
is impairment in endothelium-derived bioactivity.
Nitric oxide is produced in endothelial cells from the conversion
of l-arginine to l-citrulline through the activity of (endothelial) nitric
oxide synthase. EDNO regulates vascular tone through a dilator
action on vascular smooth muscle cells that depends on soluble
guanylyl cyclase activation and consequent increase in guanosine
monophosphate. Additional antiatherogenic functions of EDNO relate
to inhibition of platelet activity, leucocyte adhesion, and vascular
smooth muscle cell proliferation. Mechanisms underlying impaired
endothelial function in various disease states such as hypertension,
diabetes mellitus, hypercholesterolaemia, and atherosclerosis are
likely multifactorial. There is growing evidence that oxidative stress
(deﬁned as an imbalance between endogenous oxidants and
antioxidants in favour of the former) contributes to mechanisms of
vascular dysfunction. These observations ﬁt well with the recogni-
tion that increased oxidative stress may be central to the atherogenic
process.
Although the mechanism of oxidative modiﬁcation of LDL
remains unknown, the importance of oxidation can be seen by the
presence of oxidized LDL in atherosclerotic lesions. Experimentally,
the amount of oxidized LDL is reﬂective of the atherosclerotic
burden. Oxidized LDL induces a series of atherogenic processes,
including transcription of proatherogenic genes, production of
matrix metalloproteinases and tissue factor, antagonism of endothe-
lial cell production of NO, and promotion of vascular smooth muscle
cell apoptosis. The augmented production of superoxide anion also
rapidly reacts with NO to produce peroxynitrite, a potent oxidant.
However, large trials of antioxidant vitamins, including the
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto
miocardico (GISSI) Prevention Trial, the Heart Outcomes Prevention
Evaluation Study (HOPE), and the Heart Protection Study (HPS),
have not demonstrated any reduction in clinical events with
antioxidant vitamin E therapy. The antioxidants used in these trials,
however, have limitations that may have precluded an adequate test
of the hypothesis. Conventional antiplatelet therapy has also
antioxidant effects by virtue of its ability to limit production of ROS
by activated platelets. The importance of oxidative stress in the
pathogenesis of atherosclerosis makes clear that the limitations of
current therapies should not conclude therapeutic interest in this
area but foster investigation into new avenues of treatment.
There is considerable need for additional investigation into the
basic mechanisms of atherosclerosis. It is important to clarify the
differential role of HDL cholesterol metabolism and other lipid
disturbances as well as the biomechanical and rheologic factors in
development and progression of disease in the noncoronary
circulations. Greater research is needed in understanding regional
differences in plaque formation and clinical manifestations of
disease. Genetic variability across individuals and populations merits
additional exploration using genomics and proteomics. Pathophysi-
ological responses to changes in metabolic demand such as exercise
and factors that determine development of collateral vessels and
angiogenesis need greater attention. In particular, the interaction
between reduced oxygen and substrate delivery and skeletal muscle,
neurological, and metabolic function needs additional study. There is
a need for improved functional imaging and biomarkers of disease
progression and unstable patterns of atherosclerosis to assist in
understanding of regional disease pathophysiology.
doi:10.1016/j.ijcme.2015.05.007
Hypertension: Should we ablate all hypertensives? Pro
Giuseppe M.C. Rosano, MD, PhD
Cardiovascular & Cell Science Institute, St George's University of London,
London, UK
Abstracts 3
Open access under CC BY-NC-ND license.
The renal nerves are important contributors to the development
of hypertension. Patients with essential hypertension and other
disease states often have increased sympathetic drive coupled with
an increased efferent sympathetic drive to the kidneys. Increased
renal afferent activity in patients with essential hypertension is also
present. Surgical sympathectomy has been effectively used since the
'50s as a treatment for severe hypertension. More recently the
development of endovascular catheter-based technology has allowed
selective denervation of the kidney using radiofrequency (RF) energy
delivered on the renal artery lumen.
Initial clinical trials with renal ablation technique have docu-
mented the safety and efﬁcacy of this approach, however there have
been questions on the long-term safety, patient selection, deﬁnition
and level of responder rates. Furthermore, a recent randomised study
conducted in the US has shown no effect over intensiﬁcation of
medical therapy. In this study however, the ablation technique was
not adequately implemented and there was evidence that the vast
majority of patients were not ablated at all.
Catheter-based renal nerve ablation blocks both renal efferent
and afferent nerve ﬁbers. In 2009, the ﬁrst multicenter study with
catheter based renal denervation was conducted in 45 patients with
treatment-resistant hypertension. The initial cohort was subsequent-
ly expanded to 153 patients, and the follow-up duration was
increased to 2 years (Symplicity HTN-1). The average blood pressure
reductions were 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg
at 1, 3, 6, 12, 18, and 24 months after renal denervation, respectively.
Because of the absence of a control group in Symplicity HTN-1, a
multicenter, randomized, controlled trial (Symplicity HTN-2) was
performed in 106 patients randomly assigned to undergo RDN
combined with prior treatment or to maintain prior treatment alone.
Blood pressure values were reduced by an average of 32/12 mm Hg
in the renal denervation group at 6 months, whereas no change
occurred in the control group. After 6 months, more than 70% of
patients in the control group crossed over to receive renal
denervation, and these patients experienced a signiﬁcant drop in
BP similar to that observed in the initial RDN group.
A third multicenter, randomized, controlled trial (Symplicity
HTN-3) with similar inclusion criteria has been recently completed.
In this study no difference in ofﬁce-based systolic BP at 6 months nor
in ABPM were observed. However, in this study conducted in the US,
the majority of operators were unadequately trained and the vast
majority of patients did not receive adequate adiofrequency delivery
as demonstrated by the lack of buttons at renal angiography post
radiofrequency delivery. Therefore, data from Symplicity HTN3 are
not relevant to the evaluation of the effectiveness of radiofrequency
ablation, at least when performed by experienced operators.
The long-term effects of radiofrequency denervation on blood
pressure have mainly been evaluated in patients with resistant
hypertension. Resistant hypertension is deﬁned as failure to achieve
the target blood pressure in patients adherent to full tolerated doses
of ≥3 drugs that include an anti-mineralocorticoid agent. Pseudo-
resistance may also occur in patients who have white-coat hyper-
tension. The prevalence of true resistant hypertension among all
patients treated for hypertension varies markedly among clinical
trials. However, large clinical trials have reported a prevalence of
pseudo-resistance ranging from 24% to 36%. Although the exact
prevalence of true treatment resistance remains unknown, this form
of hypertension most likely occurs in a substantial proportion of
patients with hypertension.
Therefore, renal denervation is an effective procedure for the
treatment of resistant arterial hypertension. Resistance of arterial
hypertension and adherence to drug therapy must be conﬁrmed
before suggesting this therapeutic option to patients.
doi:10.1016/j.ijcme.2015.05.008
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An estimated 30%–40% of the adult population in the western world
has arterial hypertension. Elevated blood pressure (BP) is directly related
to increased cardiovascular risks and increased coronary heart disease. It
has also been shown that if BP is reduced cardiovascular events can be
reduced with a beneﬁt that is independent on age. However, the
percentage of patients achieving adequate BP control to guideline target
values remains low ranging from 20% to 56%. Poor compliance is the
main cause of inadequate BP control.
Resistant hypertension has been deﬁned as BP that remains above
goal in spite of the concomitant use of antihypertensive medications
from ≥3 drug classes one of which should be a diuretic. Individuals
with controlled BP using ≥4 drug classes are also considered to have
resistant hypertension.
With the failure of drug therapy to control BP inpatientswith resistant
hypertension, there is a need for the development of therapeutic strat-
egies to manage resistant hypertension, overcoming poor compliance.
The sympathetic nervous system (SNS) has an important regulatory
role in the body. The neural control of the kidney is of pivotal importance
for activation of the rennin angiotensin aldosterone system aswell as for
control of volume and sodium homeostasis.
The renal nerves play a relevant role in the pathophysiology of
arterial hypertension. Patients with arterial hypertension have
increased efferent sympathetic drive to the kidneys. Hypertension
is also associated with an increased rate of sympathetic-nerve ﬁring.
With the evidence of the pivotal role of SNS hyperactivity in arterial
hypertension it become obvious to therapeutically denervate the kidneys
in order to treat arterial hypertension. Renal denervationhas been applied
successfully to prevent or ameliorate hypertension in a variety of
experimental models. Non-selective surgical sympathectomy was effec-
tively used for lowering of BP in severe hypertension. However, surgical
mortality rates were signiﬁcant at 4%, and there were multiple long-term
complications including signiﬁcant hypotension, erectile dysfunction,
bladder and bowel dysfunction, and Raynaud's phenomenon.
Recently developed endovascular catheter-based technology
allows safer denervation of the renal sympathetic nerves in the
adventitia of the renal arteries with a minimally invasive procedure
usually performed via femoral artery access.
Although, initial observational data suggested a large beneﬁt of
catheter based renal denervation in patients with resistant denervation,
a recent randomised, sham controlled study has demonstrated no beneﬁt
of this technique over intensive monitored control of blood pressure.
Therefore, based on current clinical evidence, RSD is only indicated for
resistant severe essential hypertension with no signiﬁcant renal impair-
ment (estimated GFR ≥45mL/min/1.73 mL2), and suitable renal artery
anatomy. Suitable renal artery anatomy means renal arteries with dia-
meters of 4 mm or more, and lengths of 20mm or more without signiﬁ-
cant renal stenosis (b50%), or history of prior renal artery angioplasty and
stenting. Furthermore, patients undergoing this procedure should not
have signiﬁcant stenotic valve heart disease, history of acute coronary
syndrome, type 1 diabetes, and should be clinically stable, without history
of cerebrovascular accident in the preceding 3–6 months.
Percutaneous renal denervation has generated a lot of interest in
the treatment of refractory hypertension. However, on the basis of
the present experience it appears to be indicated for the treatment of
resistant hypertension only in a limited proportion of patients.
Because of the criticisms raised by the Symplicity HTN programs
more studies are needed to assess the role of radiofrequency ablation
in the management of refractory arterial hypertension.
doi:10.1016/j.ijcme.2015.05.009
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